Clinical Everolimus Experience in Pediatric Renal Transplant Patients
Articles > Article · 2013
Authors: N. DINCEL, İpek KAPLAN BULUT, Taylan Özgür SEZER, S. MIR, C. HOSCOSKUN
TRANSPLANTATION PROCEEDINGS, Journal Indexed in SCI Expanded, International, 2013, vol 45, pp 913-916
DOI: 10.1016/j.transproceed.2013.02.076
Summary
Objective. Everolimus is a potent immunosuppressive agent that has antiproliferative activities. This study sought to share our experience among renal transplanted children who required conversion from calcineurin inhibitors (CNIs) to the mammalian target of rapamycin inhibitor everolimus.